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James A. Phero, DDS, MD,* Victor T. Warren, BS,y Anson G. Fisher, BA,z
Eric M. Rivera, DDS,x Pooja T. Saha, BSPH,k Glenn Reside, DDS,{
Ceib Phillips, PhD, MPH,# and Raymond P. White, Jr, DDS, PhD**Purpose: Buffering local anesthetics with epinephrine (Epi) offers clinicians options not often consid-
ered. This study assessed outcomes for pulpal anesthesia, pain on injection, and time to midface numbness
for buffered 1% lidocaine with 1:100,000 Epi versus nonbuffered 2% lidocaine with 1:100,000 Epi.
Materials and Methods: In this trial with a randomized, crossover design, buffered 1% lidocaine was
compared with nonbuffered 2% lidocaine. Subjects were adult volunteers who served as their own con-
trols. The predictor variables were alternate drug formulations. The outcome variables were subjects’
responses to cold and electric pulp testing (EPT) stimulation of the maxillary first molar and canine,
pain levels during the injection, and time to midface numbness. After maxillary field blocks with 40 mg
of buffered lidocaine or 80mg of nonbuffered lidocaine, subjects reported pain on injection and responses
of the maxillary first molar and canine after cold and EPT stimulation. Teeth were tested before field block
and at 30-minute intervals until a positive response was detected. Two weeks later, subjects were tested
with the alternate drug combinations. For all outcome variables, assessment of treatment difference, calcu-
lated as 1% buffered minus 2% nonbuffered, was performed with the Wilcoxon rank sum test with signif-
icance at P < .05.
Results: More of the 24 subjects were women and Caucasian. The median age was 23.5 years (interquar-
tile range, 21, 25 years), and the median bodyweight was 155 lb (interquartile range, 128.5, 176.5 lb). Pain
levels during the injection were significantly lower for 1% buffered lidocaine, with P = .04. Times to
response after injection were not significantly different between the 2 drug formulations for the cold
test on a molar, with P = .08, or the cold test on a canine, with P = .22. However, times to response
were significantly longer for nonbuffered drugs for EPT on the molar and canine, both with P = .01.
Conclusions: Buffering 1% lidocaine with 1:100,000 Epi reduces the pain on injection with a maxillary
field block and results in similar lengths of pulpal anesthesia tested with a cold stimulus as compared with
nonbuffered 2% lidocaine with 1:100,000 Epi.
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2072 MAXILLARY FIELD BLOCK USING LIDOCAINECommercially available local anesthetic drugs formu-
lated with epinephrine (Epi) have a low pH to prolong
shelf life, usually around pH 3.5. After the drug is
injected, it is buffered by tissue fluid to a more neutral
pH. Because only the unionized form of the drug pen-
etrates the targeted nerve membrane, more of the
active drug is available in the unionized form when
the pH of the injected local anesthetic solution is
closer to the drug’s pKa.
1 The pKa is the pH when
the unionized and ionized molecules of the drug are
equal. For lidocaine, the pKa is approximately 8.0
with minor variation dependent on temperature. The
drug injected at a neutral pH eliminates the time lag
for buffering by tissue fluid, making the maximum
unionized form of the anesthetic drug available at
the site of injection immediately while retaining the
desired qualities of the Epi.
Because more of the lidocaine in the unionized form
is in proximity to the targeted nerve fibers immedi-
ately when the lidocaine with Epi is buffered, it is plau-
sible that a lower drug dosage might be effective.
Warren et al2 have reported that buffered 1% lidocaine
with 1:100,000 Epi for a mandibular nerve block has a
comparable clinical effect, in terms of duration of
pulpal anesthesia, to commercially available nonbuf-
fered 2% lidocaine with Epi. In addition, 70% of
subjects reported significantly lower pain scores after
receiving buffered 1% lidocaine as compared with
nonbuffered 2% lidocaine, with P < .01.
The purpose of this study with a crossover design,
with each participant serving as his or her own con-
trol, was to assess clinical outcomes: pulpal response
to cold and electric pulp testing (EPT) on the maxillary
first molar and canine after a field block with buffered
1% lidocaine with 1:100,000 Epi as compared with
nonbuffered 2% lidocaine with 1:100,000 Epi. In addi-
tion, data were collected to substantiate previous
reports of less pain during the injection and time to
numbness after a field block in the skin and after a
mandibular nerve block with buffered 1% lidocaine
with 1:100,000 Epi as compared with the 2% nonbuf-
fered drug.2-9 We hypothesized that no differences in
the outcomes studied would be detected when
comparing the 2 drug formulations. The specific
aims included determining subjects’ reported
differences between drug formulations in perceived
pain on injection and the length of time, in
30-minute intervals after injection, to a return to sensa-
tion tested by cold and EPT stimulation on the maxil-
lary first molar and canine.
Materials and Methods
STUDY DESIGN AND SAMPLE
To address the research purpose, we designed and
implemented an institutional review board–approvedstudy with a crossover design. Each participant served
as his or her own control. The recruited study popula-
tion, 24 subjects, was composed of adult volunteers
tested at theUniversity of North CarolinaOral andMaxil-
lofacial Surgery Clinic 2 weeks apart in May 2016. No
treatment other than the study tests was rendered. To
be included in the study sample, subjects had to meet
the following criteria: healthy individualswith American
Society of Anesthesiologists class I or II, aged between
20 and 30 years, no allergy to lidocaine, and no receipt
of a local anesthetic in the previous month. Individuals
were excluded if they did not speak English or did not
live within 30 miles of the clinic.VARIABLES
The predictor variables for the study were the alter-
nate drug formulations: 4 mL of buffered 1% lidocaine
(40 mg) with 1:100,000 Epi or 4 mL of nonbuffered 2%
lidocaine (80 mg) with 1:100,000 Epi. The syringe for
the buffered drug had an added volume of 0.4 mL
to compensate for the added bicarbonate solution.
The outcome variables were subjects’ subjective
responses to cold and EPT stimulation of the maxillary
first molar and canine pain during the injection and
time until the midface was numb.DATA COLLECTION
Subjects were randomized to receive injections in-
traorally 2 weeks apart for maxillary field blocks
with the 2 drug formulations: buffered and nonbuf-
fered. The buffering kit connected the vials containing
the local anesthetic and bicarbonate with Luer compo-
nents allowing each milliliter of buffered local anes-
thetic drug to be buffered in turn with 0.1 mL of
bicarbonate (Anutra Medical, Research Triangle Park,
NC). A detailed description of the buffering kit is pro-
vided on the manufacturer’s Web site (AnutraMedical.
com). Subjects and clinicians recording their re-
sponses were masked to the drugs administered.
A full-time surgery faculty member administered the
maxillary field blocks. The surgeon was blinded to the
drug administered during each clinical session. In
week 1, each participant received a unilateral infiltra-
tion injection on the facial and palate to anesthetize
the maxillary first molar and canine. Two weeks later,
sufficient to exceed the washout period for the drug,
the field block on the same side of the jaw involved
the alternate local anesthetic combination.
Pulpal anesthesia—blockage of sensory nerves
within the teeth—was assessed by subjective reports
from subjects after a cold test and EPT were applied
to the maxillary first molar and canine. Both tests
were conducted at baseline and at 30-minute intervals
until the baseline positive response to testing was at-
tained. If subjects did not feel a sensation by
Table 1. DEMOGRAPHIC CHARACTERISTICSOF STUDY
SUBJECTS ALTERNATELY RECEIVING BUFFERED 1%
AND NONBUFFERED 2% LIDOCAINE WITH 1:100,000
EPINEPHRINE (N = 24)
Data
Gender, n
Male 10 (42%)
Female 14 (58%)
Median weight (IQR), lb 155 (128.5, 176.5)
Median age (IQR), yr 23.5 (21, 25)
Ethnicity or race, n
White 14 (58%)
African American 4 (17%)
Asian 4 (17%)
Other 2 (8%)
Abbreviation: IQR, interquartile range.
Phero et al. Maxillary Field Block Using Lidocaine. J Oral Maxillo-
fac Surg 2017.
PHERO ET AL 2073120 minutes, they were recorded as having felt a posi-
tive sensation at some time greater than 120 minutes.
Time increments were ranked as 1 (30 minutes)
through5 (>120minutes) for analyses. Cold stimulation
targeted unmyelinated C sensory nerve fibers, and EPT
targeted myelinated A delta sensory nerve fibers.10-13
Assessment of pain level during the injection was
reported by each participant using a 10-point Likert-
type scale anchored by ‘‘no pain’’ and ‘‘worst pain
imaginable.’’ A timed assessment was performed for
clinical onset of anesthesia by the participant report-
ing the time after injection to a numb midface.
DATA ANALYSES
The sample size of 24 subjects was chosen to meet
limitations on budget and clinic availability. This sam-
ple was sufficient to provide data for bivariate ana-
lyses, assess whether a larger study is warranted, and
provide estimates for sample size calculation for larger
studies. For all outcome variables, an assessment of
treatment difference, calculated as 1% buffered minus
2% nonbuffered, was performed with the Wilcoxon
rank sum test with Proc NPAR1WAY (SAS, version
9.3; SAS Institute, Cary, NC).14 Statistical significance
was set at P < .05 for all outcomes.
Results
Of the 24 subjects completing the study protocol,
58% were women; 58% were white, 17% were
African America, 17% were Asian, and 8% were other
ethnic designations (Table 1). The median age was
23.5 years (interquartile range [IQR], 21, 25 years),
and the median body weight was 155 lb (IQR, 128.5,
176.5 lb).
When drug formulation times were combined
(48 scores), the median time to return of sensation
after injection for the cold test on a molar was
90 minutes. The median difference in time to recovery
of sensation between 2% nonbuffered and 1% buffered
lidocaine was approximately 15 minutes (median
rank, 0.5 time increments). Half of the subjects
reported the same time or a longer time to a positive
response to cold on the maxillary molar after buffered
1% lidocaine as compared with nonbuffered 2% lido-
caine. Time to sensation return was not significantly
different, on average, between the 2 drug formulations
for the cold test on a molar, with P = .08.
When drug formulation times were combined
(48 scores), the median time to return of sensation
after injection for the cold test on a canine was approx-
imately 75 minutes (median rank, 1.5 time incre-
ments). The median difference in time to recovery of
sensation between 2% nonbuffered and 1% buffered
lidocaine was 0 minutes for the cold test on a canine.
Seventy-one percent of subjects reported the sametime or a longer time to a positive response to cold
on the maxillary canine after buffered 1% lidocaine
as compared with nonbuffered 2% lidocaine. Time to
sensation return was not significantly different, on
average, between the 2 drug formulations for the
cold test on a canine, with P = .22.
For the EPT on a molar, the median difference in
time to recovery of sensation between 2% nonbuffered
lidocaine and 1% buffered lidocaine was 30 minutes
(median, 1 time increment). Only 35% of subjects re-
ported the same time or a longer time to a positive
response to EPT on the maxillary molar after buffered
1% lidocaine as compared with nonbuffered 2% lido-
caine. Time to sensation was significantly different,
on average, in favor of nonbuffered 2% lidocaine
between the 2 drug formulations for the EPT on a
molar (P = .01).
For the EPT on a canine, the median difference in
time to recovery of sensation between 2% nonbuffered
and 1% buffered lidocaine was 30 minutes (median, 1
time increment). Almost half the subjects (48%)
reported the same time or a longer time to a positive
response to EPTon the maxillary canine after buffered
1% lidocaine as compared with nonbuffered 2% lido-
caine. Time to sensation was significantly different,
on average, in favor of nonbuffered 2% lidocaine for
the EPT on a canine (P = .01).
When drug formulation times were combined, the
median score for pain level during the injection on
the 10-point Likert-type scale for the 24 subjects (48
scores) was 4 (IQR, 2.5, 5). Pain levels were lower,
on average, by 1 unit for 1% buffered lidocaine (IQR,
–2.5, +1). Of 24 subjects, 58% reported lower pain
scores after buffered 1% lidocaine as compared with
nonbuffered 2% lidocaine. The median difference in
pain level during the injection between the 2 drug
2074 MAXILLARY FIELD BLOCK USING LIDOCAINEcombinations significantly favored 1% buffered lido-
caine, with P = .04.
When drug formulation times were combined, the
median time to midface numbness for the 24 subjects
(48 scores) was 2 minutes (IQR, 1, 6 minutes). Of 24
subjects, 58% reported a lower time to midface numb-
ness after buffered 1% lidocaine as comparedwith non-
buffered 2% lidocaine. The median difference in time
tomidface numbness between the 2 drug formulations
was –2.5 minutes (IQR, –5.5, +1.5 minutes; P = .33).Discussion
The data we report suggest that buffering 1% lido-
caine with 1:100,000 Epi just before a maxillary field
block offers clinicians options not often considered.
After testing of a maxillary first molar and canine a
cold stimulus, no differences in time to recovery
of sensation were recorded between the 2 drug
combinations—buffered 1% lidocaine and nonbuf-
fered 2% lidocaine. At least half of the subjects in the
study reported that the duration of pulpal anesthesia
after injection of buffered 1% lidocaine with Epi was
comparable with that of nonbuffered 2% lidocaine
with Epi. A contrasting pattern resulted with electrical
pulp stimulation (EPT) of the first molar and canine.
Significant differenceswere detectedwith EPT in favor
of nonbuffered 2% lidocaine with Epi.
Our data also suggest that injection of buffered 1%
lidocaine with Epi for a maxillary field block was signif-
icantly less painful than injection of the nonbuffered
2% drug. Although 58% of subjects reported a lower
time to midface numbness after buffered 1% lidocaine
as compared with nonbuffered 2% lidocaine, the me-
dian time to midface numbness was less predictable
and not significantly different for the 2 drugs studied.
Are the differences we report for the cold test and
EPT plausible even though the outcomes contrast
with those reported for a mandibular nerve block?
A review by Lin and Chandler10 suggests an
explanation. The response to cold stimulation is
mediated by unmyelinated C sensory nerve fibers
located throughout the body of the pulp. These nerve
fibers are associated with dull, lingering pain. The
myelinated A delta sensory nerve fibers terminate at
the pulpal-dentin junction relatively closer to the
tooth surface. These fibers are associated with sharp,
acute pain. On the basis of their terminal anatomic
structure and location in the pulp, the A delta sensory
fibers have a lower threshold for a response than the
C sensory fibers. With a mandibular nerve block, the
greatest volume of injected local anesthetic is
concentrated in one anatomic region, close to the
nerve trunk. With a maxillary field block, as the
term ‘‘field’’ suggests, the injected local anesthetic is
spread across a wider anatomic area as comparedwith a nerve block. Further investigation is needed
to determine whether higher dosages of buffered
1% lidocaine with Epi would produce similar out-
comes with a maxillary field block as reported for a
mandibular nerve block.
The data suggesting less pain on injection for a
maxillary field block are similar to data in the literature
regarding skin. Significantly less pain on injection of
buffered 1% lidocaine with Epi as compared with the
nonbuffered drug has been reported for cosmetic pro-
cedures with a field block in skin, particularly for sen-
sitive anatomic sites. For example, Lee et al5 reported
less pain with buffered lidocaine as compared with
nonbuffered in surgery of the hand, a traditionally
painful anatomic site for injections. Masters4 found
similar results with buffered local anesthetic adminis-
tered for plastic surgery procedures; half of the pro-
cedures were performed on the face.
Clinicians should consider that the data we report
have limitations. Although the experimental design
compared outcomes for the same participant and we
did not detect a ‘‘period effect,’’ all data required sub-
jective responses. Responses to stimulation of the
test molar and canine are commonly used in dental
practice, applied clinically to assess ‘‘tooth
vitality.’’ The assumption is that a positive response is
accompanied by an adequate pulpal blood supply
and a negative response is associated with necrotic
pulp. Our method to assess blockage of sensory nerve
responses by local anesthetics has been applied in
experimental protocols by other investigators as early
as the mid 20th century, but the tests were not origi-
nally designed for this application.10
It was clear that the local anesthetic buffered just
before injection was associated with significantly less
pain during the injection for a maxillary field block, a
benefit to patients. However, reported pain levels
were low, with an average of 4 on a 10-point
Likert-type scale, irrespective of the test drug. Clini-
cians must weigh these potential benefits in planning
short, simple procedures accomplished with local
anesthesia alone as compared with longer, complex
procedures with local anesthesia and sedation. The
subjects studied were all young, healthy adults.
Potential patients with a more compromised health
status or a long history of complex dental problems
may report different responses.
In summary, reducing drug dosages while retaining
the benefits of effective responses to local anesthetics
should be explored further. Clear benefits could
accrue to pediatric patients whose lidocaine drug dos-
ages and treatment are now limited by caution not to
exceed maximum blood lidocaine levels based on
body weight. Other patients may also benefit, particu-
larly those with compromised liver function. Similar
studies should be conducted for outcomes with other
PHERO ET AL 2075local anesthetics. For example, buffered 2% articaine
may be as effective as the 4% drug, minimizing or elim-
inating the chance of sensory nerve deficit after a
mandibular nerve blockwith 4% articainewhile retain-
ing the positive properties of the drug, including ready
diffusion in tissue and a short elimination half-life in
the bloodstream.
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